159
Views
2
CrossRef citations to date
0
Altmetric
Commentaries

Improving end-of-life care for patients with leukemia: is inpatient death the right measure?

ORCID Icon
Pages 2546-2548 | Received 09 Oct 2020, Accepted 13 Oct 2020, Published online: 29 Oct 2020
 

Disclosure statement

Consulting/honoraria/advisory boards: AbbVie, Agios, Amgen, AstraZeneca, CareVive, BMS/Celgene, Daiichi-Sankyo, Flatiron, Helsinn, Heron, Otsuka, Medtronic, Pfizer, Seattle Genetics, Welvie: Speakers bureaus: Agios, AbbVie, and Bristol Myers Squibb/Celgene. Research funding: American Cancer Society, AstraZeneca, BMS, Duke University, NINR/NIH, Jazz Pharmaceuticals, Seattle Genetics. Royalties: UpToDate.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.